Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Company Overview

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.

Key Stats

• Today's Range: C$4.56 to C$5.10
• 50-Day Range: C$3.82 to C$5.10
• 52-Week Range: C$2.47 to C$5.10
• Volume: 128,735 shs
• Average Volume: 48,813 shs
• Market Capitalization: C$161.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Medexus Pharmaceuticals Stock Analysis - MarketRank™

Medexus Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Medexus Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Medexus Pharmaceuticals is -72.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medexus Pharmaceuticals is -72.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medexus Pharmaceuticals has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MDP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medexus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Medexus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Medexus Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Medexus Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medexus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.14% of the stock of Medexus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

3.24% of the stock of Medexus Pharmaceuticals is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MDP
• CIK: N/A
• Web: www.medexus.com
• Phone: 877-633-3987
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 31.23
• P/E Growth: N/A
• Net Income: C$3.26 million
• Net Margins: -2.37%
• Pretax Margin: N/A
• Return on Equity: -4.55%
• Return on Assets: 4.89%

Debt

• Debt-to-Equity Ratio: 45.45
• Current Ratio: 1.19
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$99.33 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.53 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 31,660,000
• Free Float: N/A
• Market Cap: C$161.47 million
• Optionable: Not Optionable
• Beta: 0.53